ONC - BeiGene Ltd PEG Multiple
The use of AI for accelerated molecule selection is generating intrigue regarding the development pace of BeiGene Ltd (ONC). The PEG ratio visualizes the market valuation of these achievements, where the 0.54 metric confirms the current level. The company's foundation relies on expansion into the US and EU via its Chinese base, while modernized sterile plants ensure the stable production of innovative medicines.
Analytical breakdowns for BeiGene Ltd (ONC)
- market price and analyst price targets:
- market capitalization statistics:
- balance sheet equity data:
- issuer credit burden and liquidity indicators:
- earnings and valuation multiples information:
ONC - Company Net Income|Net Profit Forecast BeiGene Ltd|ONC - P/E Multiple|Projected Price to Earnings Ratio BeiGene Oncology|ONC - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation BeiGene Corp|ONC - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months BeiGene|ONC - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months beigene.com|ONC - Earnings growth in current year|Projected earnings per share growth rate for next year BeiGene Ltd
General company analysis:ONC, BeiGene Ltd.
BeiGene Ltd (ONC) possesses absolute pricing power in the oncology market, creating a foundation for rapid profit scaling and making the analysis of expansion rates critically important. The GURU.Markets toolkit, via the ratio of company value to growth rates, allows for a comparison of the current P/E multiple with revenue dynamics, where a value below one signals that the asset is undervalued relative to its potential.
Competing companies
Price/Earnings to Growth Multiple Halozyme Therapeutics, Inc. HALO|RevMed - Price/Earnings to Growth Multiple|PEG Multiple Ascentage Pharma Corp AAPG|CGON - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio URGN (urogen.com)|BCAX: PEG Multiple|Price to Earnings Adjusted for Growth Rate Personalis Inc (PSNL)|ERAS (Erasca Corp) - PEG Multiple|Price/Earnings to Growth Ratio DCTH|PEG Multiple YMAB|AURA - Price to Earnings Adjusted for Growth Rate|PEG Multiple CADL (Candel Therapeutics, Inc.)|Growth-Adjusted Market Cap to Net Income Accuray Inc (ARAY)|SELLAS Life Sciences Group Inc. - PEG Multiple|Price to Net Income Growth Ratio Actuate Therapeutics Inc (ACTU)|CTOR: PEG Multiple|Price to Earnings Adjusted for Growth Rate TuHURA Biosciences (HURA)|Price/Earnings to Growth Ratio Protara Therapeutics, Inc.|Growth-Adjusted P/E Ratio FATE (Fate Therapeutics Inc)|PEG Multiple WHWK|TCRX - Price to Earnings Adjusted for Growth Rate|Champions Oncology, Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio XBIT|CVM - Price/Earnings to Growth Ratio|OSTX: Price/Earnings to Growth Ratio|RADX (Radiopharm Theranostics Limited) - Price/Earnings to Growth Multiple|ARTV: Company Value to Earnings Growth Ratio|ANL (Adlai Nortye Ltd) - PEG Multiple|Growth-Adjusted P/E Ratio VERU (verupharma.com)|Price/Earnings to Growth Ratio Tempest Therapeutics, Inc. (TPST)|XLO - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Renovaro RENB|MURA: Growth-Adjusted P/E Ratio|Kairos Pharma Inc - PEG Multiple|OnKure Therapeutics Inc (OKUR) - Price/Earnings to Growth Multiple|GDTC: PEG Multiple|Price/Earnings to Growth Multiple Curis|APLM (Apollomics Inc.) - PEG Multiple|PEG Multiple Tharimmune Corporation|Price/Earnings to Growth Ratio Advanced Biomed Inc (ADVB)|genprex.com - Growth-Adjusted P/E Ratio|PEG Multiple CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Price/Earnings to Growth Multiple|Xenetic Bio - PEG Multiple|Price to Earnings Adjusted for Growth Rate Salarius Pharma|Purple Biotech (PPBT) - Price/Earnings to Growth Ratio|American Oncology Network, Inc. - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Multiple BGNE|CKPT: Growth-Adjusted Payback Ratio|PEG Multiple ELEV|Price/Earnings to Growth Multiple icadmed.com ICAD|Ikena Oncology - Price/Earnings to Growth Multiple|PEG Multiple notablelabs.com NTBL|VIRX - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio MOR (MorphoSys Inc)|NAYA: PEG Multiple|Price to Earnings Adjusted for Growth Rate Ascentage (AAPGV)
